Interpace Diagnostics Group Inc (NASDAQ:IDXG) shares saw an uptick in trading volume on Tuesday . 2,760,939 shares changed hands during trading, an increase of 37% from the previous session’s volume of 2,012,906 shares.The stock last traded at $1.06 and had previously closed at $0.94.

A number of brokerages recently commented on IDXG. Maxim Group reiterated a “buy” rating and set a $5.00 target price on shares of Interpace Diagnostics Group in a research note on Tuesday, November 14th. ValuEngine raised shares of Interpace Diagnostics Group from a “strong sell” rating to a “sell” rating in a research report on Monday, September 11th.

The stock has a market capitalization of $28.46, a PE ratio of 0.35 and a beta of 1.58.

An institutional investor recently bought a new position in Interpace Diagnostics Group stock. Sabby Management LLC purchased a new position in shares of Interpace Diagnostics Group Inc (NASDAQ:IDXG) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 529,819 shares of the business services provider’s stock, valued at approximately $476,000. Sabby Management LLC owned approximately 2.39% of Interpace Diagnostics Group as of its most recent SEC filing. 5.87% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Interpace Diagnostics Group (IDXG) Sees Unusually-High Trading Volume” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.watchlistnews.com/interpace-diagnostics-group-idxg-sees-unusually-high-trading-volume-2/1784005.html.

About Interpace Diagnostics Group

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with Analyst Ratings Network's FREE daily email newsletter.